Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by MGO One Seven LLC

MGO One Seven LLC increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 68.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,742 shares of the pharmaceutical company's stock after purchasing an additional 2,336 shares during the quarter. MGO One Seven LLC's holdings in Vertex Pharmaceuticals were worth $2,312,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Dark Forest Capital Management LP grew its position in Vertex Pharmaceuticals by 54.6% in the 4th quarter. Dark Forest Capital Management LP now owns 1,657 shares of the pharmaceutical company's stock worth $667,000 after purchasing an additional 585 shares during the last quarter. Alta Advisers Ltd increased its holdings in shares of Vertex Pharmaceuticals by 24.4% in the fourth quarter. Alta Advisers Ltd now owns 871 shares of the pharmaceutical company's stock valued at $351,000 after purchasing an additional 171 shares in the last quarter. Fayez Sarofim & Co acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $4,185,000. Stifel Financial Corp boosted its stake in Vertex Pharmaceuticals by 32.3% during the 4th quarter. Stifel Financial Corp now owns 124,844 shares of the pharmaceutical company's stock worth $50,275,000 after acquiring an additional 30,512 shares during the last quarter. Finally, TD Waterhouse Canada Inc. increased its holdings in shares of Vertex Pharmaceuticals by 260.2% in the fourth quarter. TD Waterhouse Canada Inc. now owns 8,840 shares of the pharmaceutical company's stock worth $3,560,000 after acquiring an additional 6,386 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Truist Financial raised their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Scotiabank upped their price objective on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research report on Tuesday, February 11th. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Morgan Stanley increased their price target on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 11th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, April 22nd. Ten research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $514.91.

Vertex Pharmaceuticals Trading Up 0.5 %

Shares of Vertex Pharmaceuticals stock traded up $2.65 on Monday, hitting $496.49. 1,503,332 shares of the company traded hands, compared to its average volume of 1,338,044. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. The stock's 50 day moving average price is $489.78 and its 200-day moving average price is $466.28. The company has a market cap of $127.49 billion, a PE ratio of -225.68, a PEG ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.